陇神戎发(300534) - 2021 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2021 was CNY 59,003,520.44, a decrease of 18.56% compared to the same period last year[3] - Net profit attributable to shareholders was a loss of CNY 8,480,312.60, a decline of 282.15% year-on-year[3] - Total operating revenue for the third quarter was CNY 166,686,957.67, a decrease of 0.75% compared to CNY 167,939,350.02 in the previous year[21] - Net profit for the period was a loss of CNY 7,123,107.42, an improvement from a loss of CNY 9,762,125.59 in the previous year[22] - The company reported a loss per share of CNY -0.0270, compared to CNY -0.0421 in the same quarter last year[23] Cash Flow and Financial Position - Cash flow from operating activities increased by 282.83% year-to-date, totaling CNY 29,739,129.06[9] - The net cash flow from operating activities for the current period is ¥29,739,129.06, a significant improvement compared to the previous period's loss of ¥16,265,855.31[26] - Total cash inflow from operating activities is ¥232,410,630.03, while cash outflow is ¥202,671,500.97, resulting in a net cash flow of ¥29,739,129.06[26] - The company has a cash balance of ¥61,708,197.65 at the end of the period, down from ¥99,203,912.35 in the previous period[26] - The company paid ¥70,000,000.00 in debt repayment during the financing activities, with a net cash flow from financing activities of -¥70,582,388.88[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 798,779,894.91, down 7.83% from the previous year[4] - The company's current assets decreased to RMB 274,121,688.89 from RMB 333,100,789.72, indicating a decline of approximately 17.7%[19] - Gansu Longshen Rongfa Pharmaceutical's cash and cash equivalents decreased to RMB 61,708,197.65 from RMB 118,188,757.06, reflecting a decline of approximately 47.8%[18] - Total liabilities decreased to CNY 66,769,376.99 from CNY 127,527,610.66 year-over-year[21] - The total equity attributable to shareholders was CNY 721,169,457.28, slightly down from CNY 729,356,249.06 in the previous year[21] Inventory and Prepaid Accounts - The company reported a 125.47% increase in prepaid accounts, primarily due to advances for medical equipment purchases[7] - Inventory increased by 46.44% as the company ramped up production to ensure supply during peak sales season[7] - The inventory increased significantly to RMB 60,852,851.97, up from RMB 41,553,533.55, representing a growth of about 46.3%[19] Research and Development - Research and development expenses were CNY 4,203,064.05, a slight increase from CNY 4,100,658.23 in the previous year[22] Other Income and Expenses - Other income increased by 93.15% year-to-date, mainly due to higher deferred income amortization[9] - The company recorded other income of CNY 4,153,721.34, up from CNY 2,150,562.94 in the previous year[22] - The deferred income decreased to CNY 21,576,750.04 from CNY 24,043,000.04 year-over-year[21] - The company experienced a credit impairment loss of CNY -1,137,351.41, an improvement from CNY -2,061,819.89 in the previous year[22] Market Expansion - The company received registration certificates for its health food products in Thailand and Kyrgyzstan, expanding its market presence internationally[15][16] - The company plans to acquire 95% equity of Puan Pharmaceutical through a combination of issuing shares and cash payment, with the transaction still undergoing auditing and evaluation[17] Audit Status - The company has not undergone an audit for the third quarter report[27]